Japan Nod Positive For Hemlibra But Shadows Linger

Japan has become the third major market after the US and EU to approve Chugai’s novel antibody Hemlibra (emicizumab) for hemophilia, adding another building block for what the company hopes will become a major international growth driver, but some uncertainties remain.

Bridge
JAPAN APPROVES HEMLIBRA

Japan’s Ministry of Health, Labour and Welfare has issued a conditional approval to Chugai Pharmaceutical Co. Ltd. ’s first-in-class antibody Hemlibra (emicizumab), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital Factor VIII deficiency (hemophilia A) who have Factor VIII inhibitors.

The product is approved in a range of once-weekly subcutaneous injection formulations from 30mg to 150mg and is awaiting a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip